Houlihan Lokey Strengthens Pharmaceutical and Life Sciences Valuation Capabilities with New Hire

Dimitri Drone Joins Firm as a Managing Director in New York

NEW YORK--()--Houlihan Lokey (NYSE: HLI), the global investment bank, today announced that Dimitri Drone has joined the firm as a Managing Director in Financial Advisory Services as part of a continued build-out of the firm’s pharmaceutical & life sciences valuation services. Mr. Drone is based in New York and will advise clients on valuation, financial, and transaction matters across the spectrum of healthcare and life sciences.

“It’s a privilege to join the Houlihan Lokey team with its long-standing reputation in valuing complex, emerging, and technology-based businesses and assets. I am looking forward to leveraging my experience serving multinational corporate clients in a commercial and transaction driven culture”

Prior to joining Houlihan Lokey, Mr. Drone was the global leader of PwC’s Deals business for the pharmaceutical & life sciences sector. During his nearly 30-year tenure with PwC, he advised corporate and private equity clients on the structuring of complex merger & acquisition transactions, alliances, partnerships and joint ventures, as well as minority investments to address financial reporting, corporate finance, and valuation issues. Mr. Drone is a leading advisor to clients on valuation principles, methodologies, and critical assumptions employed in various business enterprise, intangible asset, and security valuation exercises. He has also served clients across the spectrum of life science industries, including pharmaceuticals, biotech, medical device, diagnostics, generics, consumer, animal health, and contract research organizations.

“As we continue to assist corporate and financial clients across the healthcare continuum in increasingly challenging and global transactions, we are seeking established expertise with leading companies around the world. Welcoming Dimitri to the Houlihan Lokey team continues our industry growth strategy and commitment to providing market-leading valuation and transaction advisory services to pharmaceutical & life sciences companies and investors,” said Jack Berka, Senior Managing Director and Global Head of Financial Advisory Services.

“It’s a privilege to join the Houlihan Lokey team with its long-standing reputation in valuing complex, emerging, and technology-based businesses and assets. I am looking forward to leveraging my experience serving multinational corporate clients in a commercial and transaction driven culture,” said Mr. Drone.

Mr. Drone holds a B.S. in Accounting from Bucknell University and an MBA in Finance and Economics from the University of Chicago’s Booth School of Business. He is a licensed Certified Public Accountant and Chartered Financial Analyst®.

About Houlihan Lokey

Houlihan Lokey (NYSE:HLI) is a global investment bank with expertise in mergers and acquisitions, capital markets, financial restructuring, valuation, and strategic consulting. The firm serves corporations, institutions, and governments worldwide with offices in the United States, Europe, the Middle East, and the Asia-Pacific region. Independent advice and intellectual rigor are hallmarks of the firm’s commitment to client success across its advisory services. Houlihan Lokey is ranked as the No. 1 M&A advisor for all U.S. transactions, the No. 1 global restructuring advisor, and the No. 1 global M&A fairness opinion advisor over the past 20 years, according to Thomson Reuters. For more information, please visit www.HL.com.

Contacts

Houlihan Lokey
Investor Relations
212.331.8225
IR@HL.com
or
Media Relations
John Gallagher, 212.331.8223
PR@HL.com

Recent Stories

RSS feed for Houlihan Lokey

Release Summary

Dimitri Drone has joined Houlihan Lokey as a Managing Director in Financial Advisory services, based in New York.

Houlihan Lokey